Bankers Pray for Successful Alnylam IPO

Santini, Laura
April 2004
Investment Dealers' Digest;4/19/2004, Vol. 70 Issue 16, p10
Trade Publication
Reports on the industrial implications of an initial public offering made by Alnylam Pharmaceuticals Inc. in determining the financing prospects for biotechnology companies in the U.S. Bear market transactions; Market capitalization; Joint ventures; Views of investors.


Related Articles

  • S.D. Biotechs to Change Strategies in '06. Weeks, Katie // San Diego Business Journal;1/2/2006, Vol. 27 Issue 1, p17 

    The article looks at the trends in the biotechnology industry in San Diego, California. Investment analysts claim that biotechnology companies will go public and outsource more science in 2006. Also, the practice of purchasing rights to other companies' technologies will continue among specialty...

  • Venture-backed IPOs jump in first quarter.  // Pensions & Investments;5/3/1999, Vol. 27 Issue 9, p31 

    Reports on the number of venture-back initial public offerings in the first quarter of 1999.

  • Guayacan scores in improved IPO market. Carmona, Jose L. // Caribbean Business;8/9/2001, Vol. 29 Issue 32, p10 

    Focuses on the financial benefits of the initial public offering (IPO) market of Grupo Guayacan Inc. (GG) in Puerto Rico. Returns of GG Funds during the second quarter of 2001; Impact of joint ventures on the market profitability of GG; Number of United States IPO handled by GG.

  • The Resurgence of European Biotech. Blau, John // Research Technology Management;Sep/Oct2011, Vol. 54 Issue 5, p3 

    This article explores the resurgence of biotechnology from Europe in 2011. It attributes the trend to renewed investor interest in investing in biotechnology companies. It discusses the advantage of partnerships entered by biotechnology companies with pharmaceutical firms. The rising issuance of...

  • European Biotech Recovers, IPOs Expected.  // BioPharm International;Jun2004, Vol. 17 Issue 6, p10 

    Reports on a study conducted by Ernst & Young Inc. which found that Europe's biotechnology industry may be recovering after a decline in 2003. Percentage decline in revenues, workers and research and development spending in the industry; Information on potential companies who will offer initial...

  • New era promises a sweeter pill. Pinniger, David // Fund Strategy;6/7/2010, p20 

    The article focuses on the opportunities offered by the biotechnology industry in providing high returns of investments. It indicates that the high returns of the biotechnology sector is triggered by the patent expiry cycle and rising competition of generic manufacturers. It shows that the...

  • Imarx Goes Public With $15M Offering; Archemix Files For IPO. Boggs, Jennifer // BioWorld Today;7/26/2007, Vol. 18 Issue 144, p1 

    The article reports on several financings within the biotechnology industry. Imarx Therapeutics Inc., thrombolytic drug developer, priced its initial public offering lower than expected, selling 3 million shares at $5 apiece for gross proceeds of $15 million. A firm specializing in aptamer-based...

  • Keys to Success: Experts Offer Tips for All Stages of Partnering. Lyle, Amanda // BioWorld International;10/15/2008, Vol. 13 Issue 42, p7 

    The article focuses on tips offered by experts at the BioWorld BioPartnering 2008 on successful deal making between biotechnology and pharmaceutical firms. Deloitte Recap Senior Analyst Michael G. McCully said there has been an increase in the number of risk-sharing deals and new models for...

  • MIXED BLESSINGS. Parr, Lauren // Estates Gazette;3/6/2010, Issue 1009, p146 

    The article focuses on the mixed condition of the real estate business in Cambridge, England in 2010 due to job cuts in the pharmaceutical industry and expansion of the biotechnology sector. Property owners fear that other firms will follow the job cuts at AstraZeneca and GlaxoSmithKline and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics